Stocktoria
PULSE BIOSCIENCES, INC. PLSE
PULSE BIOSCIENCES, INC. (PLSE) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $350,000 at a -20794.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.799 |
| Retained earnings / assets | -4.9 |
| EBIT / assets | -0.814 |
| Equity / liabilities | 5.81 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PLSE | PULSE BIOSCIENCES, INC. | 2/9 | -10.11 | — | — |
| LYRA | Lyra Therapeutics, Inc. | 2/9 | — | — | — |
| QTEX | QTREX Quantum Ltd. | 2/9 | — | — | — |
| FOFA | FAMILY OFFICE OF AMERICA, INC. | 2/9 | -13.31 | — | — |
| SKYA | SkyAI, Inc. | 3/9 | — | — | — |
| CODX | Co-Diagnostics, Inc. | 1/9 | -16.26 | — | — |
| PAVM | PAVmed Inc. | 3/9 | — | 90.2 | — |
About PULSE BIOSCIENCES, INC.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
FAQ
Is PLSE financially healthy?
PULSE BIOSCIENCES, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PLSE pay a dividend?
No, PULSE BIOSCIENCES, INC. does not currently pay a dividend.
How profitable is PLSE?
In FY2025, PULSE BIOSCIENCES, INC. had a net margin of -20794.6% and a return on equity of -90.2%.
What is the analyst price target for PLSE?
The average Wall-Street price target for PULSE BIOSCIENCES, INC. is $30.67, about 29.2% below the recent price, from 3 analysts.
Is PLSE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PULSE BIOSCIENCES, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.